Esther van den Boom - 17 Sep 2021 Form 4 Insider Report for Tyra Biosciences, Inc. (TYRA)

Role: Chief Financial Officer
Signature: /s/ John Healy, Attorney-in Fact
Issuer symbol: TYRA
Transactions as of: 17 Sep 2021
Net transactions value: $0
Form type: 4
Filing time: 17 Sep 2021, 16:44:08 UTC
Previous filing: 14 Sep 2021
Next filing: 04 Nov 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TYRA	Common Stock	Conversion of derivative security		+21,254			21,254	17 Sep 2021	See footnote	F1, F2
holding	TYRA	Common Stock						118,645	17 Sep 2021	Direct	F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	TYRA	Series A Preferred Stock	Conversion of derivative security	$0	-8,183	-100%	$0.000000^*	0	17 Sep 2021	Common Stock	21,254		Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On September 17, 2021, each share of Series A Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.
F2	Represents shares held by van den Boom Ventures LLC, of which the spouse of the Reporting Person is the managing member.
F3	Includes 71,674 shares subject to repurchase by us, which are subject to vesting.